MEREO BIOPHARMA GROUP PLC Fair Value Adjustment of Warrants
MEREO BIOPHARMA GROUP PLC (MREO) reported Fair Value Adjustment of Warrants of -$23.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC fair value adjustment of warrants for the quarter ending 2026-06-30 was -$6.00K, a 105.94% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC fair value adjustment of warrants for the quarter ending 2026-03-31 was -$17.00K.
- MEREO BIOPHARMA GROUP PLC fair value adjustment of warrants for the quarter ending 2025-12-31 was -$294.00K.
- MEREO BIOPHARMA GROUP PLC fair value adjustment of warrants for the quarter ending 2025-09-30 was -$196.00K, a 432.20% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC fair value adjustment of warrants for fiscal 2025 was -$805.00K, a 292.12% decline from fiscal 2024.
- MEREO BIOPHARMA GROUP PLC fair value adjustment of warrants for fiscal 2024 was $419.00K.
- MEREO BIOPHARMA GROUP PLC fair value adjustment of warrants for fiscal 2023 was -$245.00K.
- MEREO BIOPHARMA GROUP PLC fair value adjustment of warrants for fiscal 2022 was -$9.29M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$23.00K 10-Q · filed 2026-08-11 | -$317.00K derived: sum of 3 quarters · filed 2026-08-11 | -$513.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$17.00K 10-Q · filed 2026-05-12 | -$311.00K derived: sum of 2 quarters · filed 2026-05-12 | -$507.00K derived: sum of 3 quarters · filed 2026-05-12 | -$406.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$294.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$490.00K derived: sum of 2 quarters · filed 2026-03-19 | -$389.00K derived: sum of 3 quarters · filed 2026-08-11 | -$805.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | -$196.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$95.00K derived: sum of 2 quarters · filed 2026-08-11 | -$511.00K 10-Q · filed 2025-11-10 | -$668.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $101.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$315.00K 10-Q · filed 2026-08-11 | -$472.00K derived: sum of 3 quarters · filed 2026-08-11 | -$413.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$416.00K 10-Q · filed 2026-05-12 | -$573.00K derived: sum of 2 quarters · filed 2026-05-12 | -$514.00K derived: sum of 3 quarters · filed 2026-05-12 | -$445.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$157.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$98.00K derived: sum of 2 quarters · filed 2026-03-19 | -$29.00K derived: sum of 3 quarters · filed 2026-03-19 | $419.00K 10-K · filed 2026-03-19 |
| 2024-09-30 | $59.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $128.00K derived: sum of 2 quarters · filed 2025-11-10 | $576.00K 10-Q · filed 2025-11-10 | $771.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $69.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $517.00K 10-Q · filed 2025-08-12 | $712.00K derived: sum of 3 quarters · filed 2025-08-12 | $712.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $448.00K 10-Q · filed 2025-05-13 | $643.00K derived: sum of 2 quarters · filed 2025-05-13 | $643.00K derived: sum of 3 quarters · filed 2025-05-13 | $745.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $195.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $195.00K derived: sum of 2 quarters · filed 2025-03-26 | $297.00K derived: sum of 3 quarters · filed 2025-03-26 | -$245.00K 10-K · filed 2025-03-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $102.00K derived: sum of 2 quarters · filed 2024-11-12 | -$440.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$440.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$542.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$9.29M 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |